- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Medicis expands with purchase of LipoSonix
Scottsdale, Ariz. - Medicis' purchase of LipoSonix, an ultrasound technology used to target fat cells, will launch the company into the international marketplace and the body-contouring business, the East Valley Scottsdale Tribune reports.
Scottsdale, Ariz.
- Medicis' purchase of LipoSonix, an ultrasound technology used to target fat cells, will launch the company into the international marketplace and the body-contouring business, the East Valley Scottsdale Tribune reports.
The company is set to pay $300 million for LipoSonix, with $150 million to be paid up front to acquire the privately-owned company along with its 40 employees and research facilities. Medicis will pay the other $150 million after the U.S. approval process is complete and the technique reaches certain worldwide goals, according to the Tribune.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
